Deutsche Bank initiated coverage of Acadia Pharmaceuticals (ACAD) with a Hold rating and $22 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
Education
About Us
Working with TipRanks
Follow Us
